CDN1163, a small molecule activator of SERCA, has shown promise in modulating cellular functions related to diabetes and metabolic disorders.[46] Here, CDN1163 treatment significantly increased EF% and FS% in both Stx12‐cKO mice and wild‐type mice (Figure S8, Supporting Information), demonstrating the therapeutic potential of targeting SERCA activity to ameliorate cardiac dysfunction. This evidence concerns the gene STX12 and Other metabolic disease.